Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population

References

• Chen X, Jin Y, Tang G. New edition of pharmacology. In: The. 15th ed. Beijing: People’s Medical Publishing House，; 2005. p. 211.
   Google Scholar
• Lu Z, Yu Q. Pharmacokinetics of oxcarbazepine and its stereoselsctivity. Chin J Clin Pharmacol. 2003;19:134.
   Google Scholar
• Jiao Z, Zhong MK, Shi XJ. Therapeutic drug monitoring of anti-epilepsy drugs. China Pharm. 2004;13:386–389.
   Google Scholar
• Jiao Z, Zhong MK, Shi XJ. Frequent distribution of ultrarapid metabolisers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996;278(1):441–444.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV, Rahman A, et al. Genetic basis for low prevalence of deficient CYP2D6 oxidative drug metabolism in black Americans. J Clin Invest. 1993;91(5):2150–2154.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV, Rahman A, et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol. 1991;40(6):553–556.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV, Rahman A, et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterisation of variant CYP 2D and genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994;46(3):452–459.
   PubMed Web of Science ®Google Scholar
• Masimirembwa C, Hasler M, J A. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain Res Bull. 1997;44(5):561–571.
   PubMed Web of Science ®Google Scholar
• Masimirembwa C, Hasler M, J A. Genetic polymorphism of cytochrome P450 2D6 in a Zimbabwean population. Pharmacogenetics. 1993;3(6):275–280.
   PubMedGoogle Scholar
• Masimirembwa C, Hasler M, J A. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population: reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol. 1996;51(2):117–122.
   PubMed Web of Science ®Google Scholar
• Neyshaburinezhad N, Ghasim H, Rouini M, et al. Frequency of important cyp450 enzyme gene polymorphisms in the iranian population in comparison with other major populations: a comprehensive review of the human data. J Pers Med. 2021;11(8):804.
   PubMed Web of Science ®Google Scholar
• Yokota H, Takamura S, Furuya H, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics. 1993;3(5):256–263.
   PubMedGoogle Scholar
• Li C, Zheng X, Liu P, et al. Clinical value of lncRNA TUG1 in temporal lobe epilepsy and its role in the proliferation of hippocampus neuron via sponging miR-199a-3p. Bioengineered. 2021;12(2):10666–10673.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Gul S, Akhlaq M, et al. Estimation of polymorphisms in the drug-metabolizing enzyme, cytochrome P450 2C19 gene in six major ethnicities of Pakistan. Bioengineered. 2021;12(1):4442–4451.
   PubMed Web of Science ®Google Scholar
• Hou J, Sun E, Song J, et al. Relationship between hepatic drug-metabolizing enzymes CYP450 and traditional Chinese medicine-induced hepatotoxicity. Chin J Chin Mater Med. 2016;41(15):2774–2780.
   Google Scholar
• Liao N, Chen W. Progress in cytochrome P450 enzyme in toxicity of traditional Chinese medicines. Chin J Pharmacol Toxicol. 2012;26:402.
   Google Scholar
• Bai X, Jiang D, Wang Y. Gene polymorphism and drug metabolism of valproic acid. Chin J Drug Depend. 2007;16:241–244.
   Google Scholar
• Jiang MX. Pharmacology, the fourth edition. Beijing: People’s Publishing House; 1996. p. 99.
   Google Scholar
• Wang XE, Feng Y, Kang Y. Clinical significance of determination of blood concentration of antiepileptic drugs. Chin J Hospital Pharm. 1992;12:422–423.
   Google Scholar
• Wang W, Gong S, Li C, et al. Comparison of antiepileptic drugs on embryotoxicity in rats. Chin Pharm J. 1998;33:617–618.
   Google Scholar
• Lu T, Su L, Ji D, et al. Interaction between CYP450 enzymes and metabolism of traditional Chinese medicine as well as enzyme activity assay. Chin J Chin Mater Med. 2015;40(18):3524–3529.
   Google Scholar
• Zhao Y, Xu Z, Liu Y, et al. Research progress in genetic polymorphism of CYP450 enzymes related to drug metabolism. ClinMed J. 2017;15:1–6.
   Google Scholar
• Ariyoshi N, Takahashi Y, Miyamoto M, et al. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics. 2000;10(8):687–693.
   PubMedGoogle Scholar
• Soyama A, Saito Y, Hanioka N, et al. Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet. 2005;20(1):24–33.
   PubMedGoogle Scholar
• Zhang T, Xu S, Liu C, et al. Effects of CYP450 enzymes polymorphisms on plasma valproic acid concentration. Chin J Biochem Pharm. 2016;36:1–4.
   Google Scholar
• Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323–1338.
   PubMed Web of Science ®Google Scholar
• Sadeque AJ, Fisher MB, Korzekwa KR, et al. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther. 1997;283(2):698–703.
   PubMed Web of Science ®Google Scholar
• Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;23(4):236–241.
   PubMed Web of Science ®Google Scholar
• Oscarson M, McLellan RA, Gullstén H, et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 1999;448(1):105–110.
   PubMed Web of Science ®Google Scholar
• Tao W. Study on the relationship between CYP2A6 and CYP2B6 gene polymorphisms and sodium valproate plasma concentration. In: Innovation driven and transformational development, Proceedings of the Eleventh Annual Conference of Qingdao, 2013 (Shandong), pp. 133–137.
   Google Scholar
• Sun Y, Tan L, Song J. Effect of CYP2A6 genetic polymorphisms on serum concentration of sodium valproate. Chin J Neurol. 2006;11:745–747.
   Google Scholar
• Zhong S, Feng S, Jiang Y, et al. Determination of pharmacokinetics of sodium valproate in children with epilepsy. Chin J Appl Clin Pediatr. 1995;10:163–164.
   Google Scholar
• Zhang J, Yu L, Qu Z, et al. Interaction between sodium valproate and phenytoin or carbamazepine. Chin J Hospital Pharm. 1995;15:539–540.
   Google Scholar
• Wang X, Wang L. Effects of sodium valproate on clonazepam in pharmacokinetics and its related mechanism. Chin J Hospital Pharm. 1998;18:197–199.
   Google Scholar
• Zhou H. Pharmacogenetics. Vol. 53. Beijing: Science Press; 2001. p. 87–99.
   Google Scholar
• Liang W. Biopharmaceuticals and pharmacokinetics. Beijing: People’s Medical Publishing House; 2000. p. 102.
   Google Scholar
• Fumiyoshi Y, Hideto H, Takayuki I, et al. Novel hierarchical classification and visualization method for multiobjective optimization of drug properties: application to structure-activity relationship analysis of cytochrome P450 metabolism. J Chem Inf Model. 2008;48(2):364–369.
   PubMed Web of Science ®Google Scholar
• Hoffman SM, Fernandez-Salguero P, Gonzalez FJ, et al. Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19. J Mol Evol. 1995;41(6):894–900.
   PubMed Web of Science ®Google Scholar
• Ou J, Tan L, Sun Y. Association study between valproic acid plasma concentration and CYP286 gene polymorphism. Chin J Clin Neurosci. 2007;4:378–381.
   Google Scholar
• Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. J CNS Drugs. 2002;16(10):695–714.
   PubMed Web of Science ®Google Scholar
• Kiang TK, Ho PC, Anari MR, et al. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci. 2006;94(2):261–271.
   PubMed Web of Science ®Google Scholar
• Yang JQ, Morin S, Verstuyft C, et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol. 2003;17(3):373–376.
   PubMed Web of Science ®Google Scholar
• Imai J, Ieiri I, Mamiya K, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics. 2000;10(1):85–89.
   PubMedGoogle Scholar
• Wang SL, Huang J, Lai MD, et al. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 1995;5(1):37–42.
   PubMedGoogle Scholar
• Gu X, Zhu M, Sheng C, et al. Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding model. Eur J Clin Pharmacol. 2021;77(7):999–1009.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Wang H, Cao X, et al. Study on correlation between CYP2C19 gene polymorphism with serum valproic acid concentration and individualized medication. Int J Lab Med. 2018;39:14–16.
   Google Scholar
• Cheung NY. Law treatment of acute period of stroke: clinical observation of 98 cases. Labor Invest. 2014;32:21.
   Google Scholar
• Han R, Li Y, Wu W. Effects of CYP2C19 genetic polymorphism on plasma concentration of sodium valproate in epileptic patients. Neural Injury Funct Reconstr. 2015;10:295–297.
   Google Scholar
• Feng Y, Zhou J, Liu K, et al. Distribution of CYP2C19 gene polymorphisms related to valproic acid metabolism in children with epilepsy and individualized treatment study. Chin J Pract Nerv Dis. 2015;18:49–52.
   Google Scholar
• Tan X, Zhang Y, Wang S, et al. Study on the relationship between CYP2C9 and CYP2C19 gene polymorphisms and valproic acid concentration in epilepsy patients. Pharm Clin Res. 2011;19:123–128.
   Google Scholar
• Han L, Liu J. CYP2D6 gene polymorphism and its influence on drug metabolism, China Pharmacy. The Journal of Craniofacial Surgery. 2015;26(4):1066–1068.
   PubMedGoogle Scholar
• Neafsey P, Ginsberg G, Hattis D, et al. Genetic Polymorphism in Cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev. 2009;12(5–6):334–361.
   PubMed Web of Science ®Google Scholar
• De Gregori M, Allegri M, De Gregori S, et al. How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. Curr Drug Metab. 2010;11(3):276–282.
   PubMed Web of Science ®Google Scholar
• Fang F, Fang Z, Zhang D, et al. Gene polymorphism of CYP2D6*10 in patients with epilepsy and the effect on serum concentration of sodium valproate. China Pharm. 2015;26:1066–1068.
   Google Scholar
• Ke J, Wang D, Zhu Y. Research progress on the relationship between UGT gene polymorphisms and antiepileptic drug metabolism. Stroke Nervous Dis. 2021;28:226–228+234.
   Google Scholar
• Chen Y, Fan Q. Research progress on the effect of gene polymorphisms on the pharmacokinetics of common antiepileptic drugs. Shandong Med J. 2021;61:112–115.
   Google Scholar
• Sun Y, Zhuo W, Lin H, et al. Effects of UGT2B7-C802T and G211T genetic polymorphism on metabolism of valproic acid in epilepsy patients. Chin Hosp Pharm J. 2015;35:216–219.
   Google Scholar
• Nakamura A, Nakajima M, Yamanaka H, et al. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos. 2008;36(8):1461–1464.
   PubMed Web of Science ®Google Scholar
• He B, Wang W, Zhao X, et al. Genetic polymorphisms of UGT-glucurono-syltransferase 2B7 in Chinese healthy Han population. Chin J Clin Pharmacol. 2014;30:6–8.
   Google Scholar
• Wen Z, Xiao J, Chen X. Research progress of valproic acid pharmacogenomics. Central South Pharm. 2016;14:526–531.
   Google Scholar
• Zhang M, Li R, Zhou Y. Effect of UGT gene polymorphism on the plasma concentration of valproate acid. Central South Pharm. 2019;17:586–589.
   Google Scholar
• Cho SK, Oh ES, Park K, et al. The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers. Pharmacogenet Genomics. 2012;22(8):598–605.
   PubMed Web of Science ®Google Scholar
• Kang W, Chen J, Chai D, et al. Relationship between UGTlA6 A541G and A552C genetic polymorphism and plasma concentration of sodium valproate. Chin J Health Care Med. 2016;18:280–283.
   Google Scholar
• Xing Y, Yang L, Wang L, et al. Systematic screening for polymorphisms within the UGT1A6 gene in three Chinese populations and function prediction through structural modeling. J Pharmacogenomics. 2009;10(5):741–752.
   Google Scholar
• Wang Y, Gao L, Liu Y, et al. Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan. Chin J Contemp Pediatr. 2010;12:429–432.
   Google Scholar
• Jin L, Yang L, Ma M. Effect of UGT1A6 genetic polymorphism on serum concentration of valproic acid in Han epileptic patients. China Pharm. 2013;16:802–804.
   Google Scholar
• Nagar S, Zalatoris JJ, Blanchard RL. Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics. 2004;14(8):487–499.
   PubMedGoogle Scholar
• Tan X, Zhang X, Qiu Z. Study on the correlation between UGT1A6 gene polymorphism and valproic acid concentration in epilepsy patients. Pharm Clin Res. 2014;22:299–301.
   Google Scholar
• Mei S, Feng W, Zhu L. Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid. Seizure. 2017;51:22–26.
   PubMed Web of Science ®Google Scholar
• Guo D, Pang L, Zhou H. Progress in the pharmacogenomics of UDP-glucuronosyltransferase. Chin J New Drugs. 2011;20:1188–1193.
   Google Scholar
• Lin X, Zhang Y, Lin P, et al. Effects of UGTlA6 and UGTlA9 gene polymorphisms on blood concentration of valproic acid in Han epileptic patients. China Pharm. 2017;28:1013–1017.
   Google Scholar
• Holthe M, Rakvåg TN, Klepstad P, et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 2003;3(1):17–26.
   PubMed Web of Science ®Google Scholar
• Zou M Study on the correlation between UGT2B7 gene polymorphism and valproic acid blood concentration. MS Thesis, Central South University: Changsha, 2011.
   Google Scholar
• Zhang W, Chang YZ, Kan QC, et al. CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur J Clin Pharmacol. 2010;66(1):61–66.
   PubMed Web of Science ®Google Scholar
• Yi J, Xie H, Zhou H. Distribution of UGT1A9-2152T and UGT2B7-G211T mutations in Chinese Han population. Chin J Clin Pharmacol Ther. 2007;12:460–464.
   Google Scholar
• Zhang Q, Tang H, Lyu X, et al. Effect of udp-glucuronosyltransferase UGT2B7 genetic polymorphisms on serum valproate concentrations in children with epilepsy. J Pediatr Pharm. 2016;22:33–36.
   Google Scholar
• Chu XM, Zhang LF, Wang GJ, et al. Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur J Clin Pharmacol. 2012;68(10):1395–1401.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang W, Li Y, et al. Correlations between UGT2B7*2 gene polymorphisms and plasma concentrations of carbamazepine and valproic acid in epilepsy patients. Brain Dev. 2018;40(2):100–106.
   PubMed Web of Science ®Google Scholar
• Rowland A, Miners J, Mackenzie P. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013;45(6):1121–1132.
   PubMed Web of Science ®Google Scholar
• Mori H, Takahashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev. 2007;39(4):647–657.
   PubMed Web of Science ®Google Scholar
• Jetter A, Kullak-Ublick G. Drugs and hepatic transporters: a review. Pharmacol Res. 2020;154:104234.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, et al., International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–236. DOI:10.1038/nrd3028.
   PubMed Web of Science ®Google Scholar
• Yan J, Gao Z, Gong C, et al. Effects of quetiapine combined with sodium valproate on agitation and impulsive aggressive behavior in patients with first-episode schizophrenia. J Southeast Univ (Med Sci Edi). 2015;34:148–150.
   Google Scholar
• Ding Y, Yang F, Liu J. The effect of multidrug resistance gene haploid on the blood concentration of sodium valproate in Chinese patients with epilepsy. Chin J Clin Pharmacol Ther. 2010;15:1267–1272.
   Google Scholar
• Li J, Chen B. Research status and progress of inhibiting the function of P-glycoprotein transporter in reversing tumor multidrug resistance. J Southeast Univ (Med Sci Edi). 2018;37:359–363.
   Google Scholar
• Cuffe S, Azad A, Qiu X, et al. ABCC2 polymorphisms and survival in the princess margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. Cancer Epidemiol. 2016;41:50–56.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X, Wu J. Correlation analysis between ABCC2 gene polymorphism with blood concentration of sodium valproate and efficacy in epileptic patients. Mod Med J. 2019;47:646–651.
   Google Scholar
• Di Francia R, Siesto RS, Valente D, et al. Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. Anticancer Drugs. 2013;24(10):1069–1078.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xu H. The value of genetic polymorphisms of mycophenolate mofetil in individualized therapy. J Clin Pediatr. 2018;38:259–261.
   Google Scholar
• Chen J, Wang X, Zhou L, et al. Influence of transporter genetic polymorphisms on valproic acid blood concentration and clinical efficacy of epilepsy patients. Chin J Clin Pharmacol. 2016;32:215–217.
   Google Scholar
• Schinkel A. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 1997;8(3):161–170.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75(1):13–33.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Sheps JA, Ling V, et al. Expression analysis of ABC transporters reveals differential functions of tandemly duplicated genes in Caenorhabditis elegans. J Mol Biol. 2004;344(2):409–417.
   PubMed Web of Science ®Google Scholar
• Leschziner GD, Andrew T, Pirmohamed M, et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 2007;7(3):154–179.
   PubMed Web of Science ®Google Scholar
• Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003;348(15):1442–1448.
   PubMed Web of Science ®Google Scholar
• Makmor-Bakry M, Sills GJ, Hitiris N, et al. Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. Clin Neuropharmacol. 2009;32(4):205–212.
   PubMed Web of Science ®Google Scholar
• Huang W, Lin YS, McConn DJ, et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos. 2004;32(12):1434–1445.
   PubMed Web of Science ®Google Scholar
• Ferraro TN, Buono RJ. The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview. Epilepsy Behav. 2005;7(1):18–36.
   PubMed Web of Science ®Google Scholar
• Xi S, Teng J. Medications for epilepsy. Henan: Zhengzhou University Press; 2002. p. 229.
   Google Scholar
• Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002;3(6):561–597.
   PubMed Web of Science ®Google Scholar
• Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000;10(5):373–388.
   PubMedGoogle Scholar
• Chen CH, Wang SC, Tsou HH, et al. Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics. 2011;12(10):1397–1406.
   PubMed Web of Science ®Google Scholar
• Wang P, Yin T, Ma H. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and biotherapy. Epilepsy Res. 2015;117:52–57.
   PubMed Web of Science ®Google Scholar
• Yun W Genetic analysis of individual differences in the metabolism of antiepileptic drug carbamazepine. MS Thesis, Jilin University: Changchun, 2015.
   Google Scholar
• Wang J Correlation between CYP3A5 subfamily gene polymorphisms and carbamazepine concentration and efficacy in Chinese Han patients with epilepsy. PhD Dissertation, Fudan University: Shanghai, 2012.
   Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383–391.
   PubMed Web of Science ®Google Scholar
• Jounaïdi Y, Hyrailles V, Gervot L, et al. Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein. Biochem Biophys Res Commun. 1996;221(2):466–470.
   PubMed Web of Science ®Google Scholar
• Li D, Zhang GL, Lou YQ, et al. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther. 2007;32(1):89–95.
   PubMed Web of Science ®Google Scholar
• Ren J Study on the correlation between CYP3A5 gene polymorphism and carbamazepine plasma concentration. MS Thesis, Jilin University: Changchun, 2010.
   Google Scholar
• Park PW, Seo YH, Ahn JY, et al. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther. 2009;34(5):569–574.
   PubMed Web of Science ®Google Scholar
• Liu J, Li Y, Zhang G, et al. Effects of CYP3A5 gene polymorphism on steady state serum concentrations and therapeutic efficacy of carbamazepine in chinese han epileptic patients. China Pharm. 2014;25:3433–3435.
   Google Scholar
• Seo T, Nakada N, Ueda N, et al. Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy. Clin Pharmacol Ther. 2006;79(5):509–510.
   PubMed Web of Science ®Google Scholar
• Zhang W Study on the relationship between UGT2B7*2 gene polymorphisms and blood levels of carbamazepine and valproic acid in patients with epilepsy. PhD Dissertation, BaoTou Medical College, Inner Mongolia University of Science and Technology: Baotou, 2015.
   Google Scholar
• Qu J Effects of ABCB1, ABCC2, CYP3A5 and UGT2B7 gene polymorphisms on the efficacy of antiepileptic drugs. PhD Dissertation, Central South University: Changsha, 2012.
   Google Scholar
• Saito K, Moriya H, Sawaguchi T, et al. Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin Biochem. 2006;39(3):303–308.
   PubMed Web of Science ®Google Scholar
• Mollazadeh S, Sahebkar A, Hadizadeh F, et al. Structural and functional aspects of P-glycoprotein and its inhibitors. Life Sci. 2018;214:118–123.
   PubMed Web of Science ®Google Scholar
• Kwan P, Wong V, Ng PW, et al. Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. J Pharmacogenomics. 2009;10(5):723–732.
   Google Scholar
• Nakajima Y, Saito Y, Shiseki K, et al. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol. 2005;61(1):25–34.
   PubMed Web of Science ®Google Scholar
• Seo T, Ishitsu T, Ueda N, et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 2006;7(4):551–561.
   PubMed Web of Science ®Google Scholar
• Meng H, Guo G, Ren J, et al. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav. 2011;21(1):27–30.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zuo Z, Kwan P, et al. In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011;52(10):1894–1904.
   PubMed Web of Science ®Google Scholar
• Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia. 2001;42(12):1501–1506.
   PubMed Web of Science ®Google Scholar
• Kim WJ, Lee JH, Yi J, et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010;20(4):249–256.
   PubMed Web of Science ®Google Scholar
• Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ilae commission on therapeutic strategies. Epilepsia. 2010;51(6):1069–1077.
   PubMed Web of Science ®Google Scholar
• Zhang L. Research progress of individualized medication of phenytoin sodium guided by gene. Strait Pharm J. 2018;30:6–9.
   Google Scholar
• Kang Y, Chen M, Lai S. Potentially unsafe herb-drug interactions between a commercial product of noni juice and phenytoin-a case report. Acta Neurol. 2015;24:43–46.
   Google Scholar
• Taguchi Y, Takashima S, Tanaka K. a case of phenytoin intoxication caused by interaction between phenytoin and capecitabine. Brain Nerve. 2015;67(2):213–217.
   PubMedGoogle Scholar
• Marchi M, Besana E, Raiteri M. Oxiracetam increases the release of endogenous glutamate from depolarized rat hippocampal slices. Eur J Pharmacol. 1990;185(2–3):247–249.
   PubMed Web of Science ®Google Scholar
• Copani A, Genazzani AA, Aleppo G, et al. Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures. J Neurochem. 1992;58(4):1199–1204.
   PubMed Web of Science ®Google Scholar
• Pittaluga A, Pattarini R, Raiteri M. Putative cognition enhancers reverse kynuremc acid antagonism at hippocampal NMDA receptors. Eur J Pharmacol. 1995;272(2–3):203–209.
   PubMed Web of Science ®Google Scholar
• Vander Weide J, Steijns LS, Van Weelden MJ, et al. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogentics. 2001;11(4):287–291.
   PubMedGoogle Scholar
• Llerena A, Alvarez M, Dorado P, et al. Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain. Pharmacogenomics J. 2014;14(3):229–234.
   PubMed Web of Science ®Google Scholar
• Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998;45(6):525–538.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688–700.
   PubMed Web of Science ®Google Scholar
• Kusama M, Maeda K, Chiba K, et al. Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data. Pharm Res. 2009;26(4):822–835.
   PubMed Web of Science ®Google Scholar
• Ramasamy K, Narayan SK, Shewade DG, et al. Influence of CYP2C9 genetic-polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients. Ther Drug Monit. 2010;32(6):762–766.
   PubMed Web of Science ®Google Scholar
• Hennessy S, Leonard CE, Freeman CP, et al. CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol. 2009;49(12):1483–1487.
   PubMed Web of Science ®Google Scholar
• Anderson GD. Pharmacogenetics and enzyme induction inhibition properties of antiepileptic drugs. Neurology. 2004;63(10):S3–S8.
   PubMed Web of Science ®Google Scholar
• Xie HG, Prasad HC, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002;54(10):1257–1270.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4):625–629.
   PubMed Web of Science ®Google Scholar
• Niinuma Y, Saito T, Takahashi M, et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J. 2014;14(2):107–114.
   PubMed Web of Science ®Google Scholar
• Ren X, Wang X, Xu X, et al. Influence of CYP2C19 and CYP2C9 gene polymorphisms on phenytoin concentrations in Chinese Han epileptic patients. Chin J Clin Pharmacol. 2011;27:249–251+264.
   Google Scholar
• Yang ZF, Cui HW, Hasi T, et al. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. Genet Mol Res. 2010;9(3):1844–1851.
   PubMed Web of Science ®Google Scholar
• Zhou J, Dong F, Wu G, et al. Clinical effects of individualized administration of PHT in epileptic children guided by TDM combined with CYP2C19 genotype. Chin J Pract Med. 2019;16:98–101.
   Google Scholar
• Qi X, Huang Y, Wang Y, et al. Association of plasma sodium phenytoin concentration with CYP2C19 gene polymorphism. Chin J New Drugs. 2004;10:922–925.
   Google Scholar
• Oka E, Ohtsuka Y, Yoshinaga H, et al. Prevalence of childhood epilepsy and distribution of epileptic syndromes: a population-based survey in Okayama,Japan. Epilepsia. 2006;47(3):626–630.
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Marple AH, Shinar S, et al. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics. 2007;8(1):29–39.
   PubMed Web of Science ®Google Scholar
• Zimprich F, Sunder-Plassmann R, Stogmann E, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology. 2004;63(6):1087–1089.
   PubMed Web of Science ®Google Scholar
• Hung CC, Tai JJ, Lin CJ, et al. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics. 2005;6(4):411–417.
   PubMed Web of Science ®Google Scholar
• Vahab SA, Sen S, Ravindran N, et al. Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population. Drug Metab Pharmacokinet. 2009;24(3):255–260.
   PubMed Web of Science ®Google Scholar
• Szoeke C, Sills GJ, Kwan P, et al. Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from international pharmacogenetic cohorts. Epilepsia. 2009;50(7):1689–1696.
   PubMed Web of Science ®Google Scholar
• Jiang D, Huang C, Wang B, et al. Association study of ABCB1 genetic polymorphism and the effect of epilepsy with phenytoin treatment. Chin J Clinicians. 2015;9:2482–2486.
   Google Scholar
• Shahwan A, Murphy K, Doherty C, et al. The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish populatio. Epilepsy Res. 2007;73(2):192–198.
   PubMed Web of Science ®Google Scholar
• Smolarz B, Skalski D, Rysz A, et al. Polymorphism of the multi-drug resistance 1 gene MDRl G2677T/A (rs2032582) and the risk of drug-resistant epilepsy in the Polish adult population. Acta Neurol Belg. 2017;117(4):849–855.
   PubMed Web of Science ®Google Scholar
• Keangpraphun T, Towanabut S, Chinvarun Y, et al. Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy. J Clin Pharm Ther. 2015;40(3):315–319.
   PubMed Web of Science ®Google Scholar
• Dong L, Luo R, Tong Y, et al. Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: an analysis in a western Chinese pediatric population. Brain Res. 2011;1391:114–124.
   PubMed Web of Science ®Google Scholar
• Nurmohamed L, Garcia-Bournissen F, Buono RJ, et al. Predisposition to epilepsy–does the ABCB1 gene play a role? Epilepsia. 2010;51(9):1882–1885.
   PubMed Web of Science ®Google Scholar
• Li SX, Liu YY, Wang QB. ABCB1 gene C3435T poly-morphism and drug resistance in epilepsy:evidence based on 8604 subjects. Med Sci Monit. 2015;21:861–868.
   PubMed Web of Science ®Google Scholar
• McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994;44:17–22.
   PubMed Web of Science ®Google Scholar
• Wu W, Heebner JB, Streeter AJ. Evaluation of the absorption, excretion, pharmacokinefics and metabolism of anticonvulsant topiramate in healthy men. Pharm Res. 1994;11:336.
   Google Scholar
• Perucca E, Johannessen SI. The ideal pharmacokinetic properties of an antiepileptic drug:how close does leve tiracetam come. Epileptic Disord. 2003;5:17–26.
   PubMed Web of Science ®Google Scholar
• Gatti G, Bonomi I, Jannuzzi G, et al. The new antiepileptic drugs: pharmacological and clinical aspects. Curr Pharm Des. 2000;6(8):839–860.
   PubMed Web of Science ®Google Scholar
• Stoffel W, Bosio A. Myelin glycolipids and their functions. Curr Opin Neurobiol. 1997;7(5):654–661.
   PubMed Web of Science ®Google Scholar
• Ehmer U, Kalthoff S, Fakundiny B, et al. Gilbert Syndrome redefined: a complex genetic haplotype influences the regulation of glucuronidation. Hepatology. 2012;55(6):1912–1921.
   PubMed Web of Science ®Google Scholar
• Castel-Branco M, Lebre V, Falcao A, et al. Relationship between plasma and brain levels and the anticonvulsant effect of lamotrigine in rats. Eur J Pharmacol. 2003;482(1–3):163–168.
   PubMed Web of Science ®Google Scholar
• Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38(active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A4 promoter polymorphism. Clin Pharmacol Ther. 1999;65(5):576–582.
   PubMed Web of Science ®Google Scholar
• Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1407–1412.
   PubMed Web of Science ®Google Scholar
• Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51(16):4187–4191.
   PubMed Web of Science ®Google Scholar
• Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60(24):6921–6926.
   PubMed Web of Science ®Google Scholar
• Yang J, Cai L, Huang H, et al. Genetic variations and haplotype diversity of the UGT1 gene cluster in the Chinese population. Plos One. 2012;7(4):e33988.
   PubMed Web of Science ®Google Scholar
• Ehmer U, Vogel A, Schutte JK, et al. Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology. 2004;39(4):970–977.
   PubMed Web of Science ®Google Scholar
• Yang L, Lin W, Zhang J, et al. The relationship between the distribution characteristics of UGT1A4 gene and its polymorphisms and the blood concentration of lamotrigine in patients with epilepsy in Han nationality in northern China. Chinese J Neurol. 2015;48:180–184.
   Google Scholar
• Trottier J, Verreault M, Grepper S, et al. Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology. 2006;44(5):1158–1170.
   PubMed Web of Science ®Google Scholar
• Itaaho K, Mackenzie PI, Miners JO, et al. The configuration of the 17-hydroxy group variably influences the glucuronidation of β-estradiol and epiestradiol by human UDP-glucuronosyltransferase. Drug Metab Dispos. 2008;36(11):2307–2315.
   PubMed Web of Science ®Google Scholar
• Liston HL, Markowitz JS, De Vane L. Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol. 2001;21(5):500–515.
   PubMed Web of Science ®Google Scholar
• He Y, He F, Mo X, et al. Quantitative estimation of blood concentration of lamotrigine in Chinese Han pediatric patients with epilepsy based on UGT1A4 142T>G polymorphism and blood concentration of valproic acid. China Pharm. 2017;28:2737–2742.
   Google Scholar
• Liu L, Zhao L, Wang Q, et al. Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 −161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children. Eur J Clin Pharmacol. 2015;71(11):1341–1347.
   PubMed Web of Science ®Google Scholar
• Singkham N, Towanabut S, Lertkachatarn S, et al. Influence of the UGT2B7 −161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. Eur J Clin Pharmacol. 2013;69(6):1285–1291.
   PubMed Web of Science ®Google Scholar
• Blanca SM, Herranz JL, Leno C, et al. UGT2B7_−161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit. 2010;32(2):177–184.
   PubMed Web of Science ®Google Scholar
• Inoue K, Yamamoto Y, Suzuki E, et al. Factors that influence me pharmacokinetics of lamotrigine in Japanese patients with epilepsy. Eur J Clin Pharmacol. 2016;72(5):555–562.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang X, Li H, et al. Polymorphisms o fABCG2, ABCB1 and HNF4alpha are associated with lamotrigine trough concentrations in epilepsy patients. Drug Metab Pharmacokinet. 2015;30(4):282–287.
   PubMed Web of Science ®Google Scholar
• Milosheska D, Lorber B, Vovk T, et al. Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol. 2016;82(2):399–411.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhao L, Liang M, et al. Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in Chinese children with epilepsy comedicated with lamotrigine. Ther Drug Monit. 2016;38(3):343–349.
   PubMed Web of Science ®Google Scholar
• Miller DS, Calmon RE. Signaling pathways that regulate basal ABC transporter activity at the blood-brain barrier. Curr Pharm Des. 2014;20(10):1463–1471.
   PubMed Web of Science ®Google Scholar
• Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24(7):1227–1251.
   PubMed Web of Science ®Google Scholar
• Misaka S, Knop J, Singer K, et al. The nonmetabolized β-blocker nadolol is a substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3. Mol Pharm. 2016;13(2):512–519.
   PubMedGoogle Scholar
• Matthaei J, Kuron D, Faltraco F, et al. OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016;99(6):633–641.
   PubMed Web of Science ®Google Scholar
• Dickens D, Owen A, Alfirevic A, et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol. 2012;83(6):805–814.
   PubMed Web of Science ®Google Scholar
• Lu R Study on the correlation between drug gene polymorphism and lamotrigine plasma concentration in patients with epilepsy. PhD Dissertation, Zhejiang University: Hangzhou, 2016.
   Google Scholar
• Zhou Y, Ye W, Wang Y, et al. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai. Int J Clin Exp Pathol. 2015;8(8):9533–9542.
   PubMed Web of Science ®Google Scholar
• Yanase K, Tsukahara S, Mitsuhashi J, et al. Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. Cancer Lett. 2006;234(1):73–80.
   PubMed Web of Science ®Google Scholar
• Romermann K, Helmer R, Loscher W. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2). Neuropharmacology. 2015;93:7–14.
   PubMed Web of Science ®Google Scholar
• Urquhart BL, Ware JA, Tirona RG, et al. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics. 2008;18(5):439–448.
   PubMed Web of Science ®Google Scholar
• Furukawa T, Wakabayashi K, Tamura A, et al. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm Res. 2009;26(2):469–479.
   PubMed Web of Science ®Google Scholar
• He Y Pharmacogenomics-based research on individualized medication of lamotrigine in the treatment of epilepsy patients in southern China. PhD Dissertation, Southern Medical University: Guangzhou, 2017.
   Google Scholar
• Rivas N, Buelga DS, Elger CE, et al. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit. 2008;30(4):483–489.
   PubMed Web of Science ®Google Scholar
• Bruce CR, Brolin C, Turner N, et al. Overexpression of carnitine palmitoyltransferase I in skeletal muscle in vivo increases fatty acid oxidation and reduces triacylglycerol esterification. Am J Physiol Endocrinol Metab. 2007;292(4):E1231–1237.
   PubMed Web of Science ®Google Scholar
• Lovrić M, Božina N, Hajnšek S, et al. Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. Ther Drug Monit. 2012;34(5):518–525.
   PubMed Web of Science ®Google Scholar
• Brzaković B, Vučićević K, Kovačević SV, et al. Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients–nonlinear mixed effects modelling approach. Eur J Clin Pharmacol. 2014;70(2):179–185.
   PubMed Web of Science ®Google Scholar
• Wegner I, Wilhelm AJ, Sander JW, et al. The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. Epilepsy Behav. 2013;29(1):217–221.
   PubMed Web of Science ®Google Scholar
• Huang W Population pharmacokinetics study of lamotrigine in the treatment of epilepsy based on genetic polymorphisms of metabolic enzymes, transporters and receptors. PhD Dissertation, Guangzhou Medical University: Guangzhou, 2017.
   Google Scholar
• Chen Y, Xu S, Qiu F, et al. Influences of sodium channel gene and transporter gene polymorphisms on lamotrigine concentration. Chin J Clin Pharmacol. 2016;32:2069–2072.
   Google Scholar
• Gamble C, Williamson PR, Chadwick DW, et al. A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. Neurology. 2006;66(9):1310–1317.
   PubMed Web of Science ®Google Scholar
• Beydoun A. Safety and efficacy of oxcarbazepine: results of randomized, double-blind trials. Pharmacotherapy. 2000;20(8 Part 2):152–158.
   Web of Science ®Google Scholar
• Zou X, Chen J, An D, et al. Efficacy of low to moderate doses of oxcarbazepine in adult patients with newly diagnosed partial epilepsy. Seizure. 2015;29:81–85.
   PubMed Web of Science ®Google Scholar
• Schmidt D, Elger C. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav. 2004;5(5):627–635.
   PubMed Web of Science ®Google Scholar
• Franco V, Perucca E. The pharmacogenomics of epilepsy. Expert Rev Neurother. 2015;15(10):1161–1170.
   PubMed Web of Science ®Google Scholar
• Ma CL, Wu XY, Jiao Z, et al. SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy. Pharmacogenomics. 2015;16(4):347–360.
   PubMed Web of Science ®Google Scholar
• Ambrósio AF, Soares-Da-Silva P, Carvalho CM, et al. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002;27(1/2):121–130.
   PubMed Web of Science ®Google Scholar
• Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs. 2001;15(2):137–163.
   PubMed Web of Science ®Google Scholar
• Court MH, Duan SX, Guillemette C, et al. Stereoselective conjugation of oxazepam by human UDP-Glucuronosyltransferases (UGTs): s-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002;30(11):1257–1265.
   PubMed Web of Science ®Google Scholar
• Court MH, Hao Q, Krishnaswamy S, et al. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther. 2004;310(2):656–665.
   PubMed Web of Science ®Google Scholar
• Högler W, Wudy SA, Luef G, et al. Oxcarbazepine accelerates cortisol elimination via cytochrome P450 3A4 induction. Arch Dis Child. 2010;95(12):1065.
   PubMed Web of Science ®Google Scholar
• Andreasen AH, Brosen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on CYP3A4. Epilepsia. 2007;48(3):490–496.
   PubMed Web of Science ®Google Scholar
• Sugiyama I, Murayama N, Kuroki A, et al. Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells. Xenobiotica. 2016;46(9):765–774.
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Kagaya H, et al. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics. 2011;12(7):977–984.
   PubMed Web of Science ®Google Scholar
• Wang P Study on the correlation between CYP3A4/3A5, ABCB1 gene polymorphism and the plasma concentration of carbamazepine, oxcarbazepine and its main metabolites. PhD Dissertation, Central South University: Changsha, 2014.
   Google Scholar
• Neels HM, Sierens AC, Naelaerts K, et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med. 2004;42(11):1228–1255.
   PubMed Web of Science ®Google Scholar
• Zhou X, Ma L, Xiang Q, et al. Relationship between cytochromes P450 2C19* 2 genotype and the concentration of the active oxcarbazepine metabolite in pediatric patients with epilepsy. Chin J Clin Pharmacol. 2017;33:595–598.
   Google Scholar
• Xia D, Zuo J, Zhao D, et al. Genetic polymorphism analysis of cytochrome CYP3A4, CYP2C9, CYP2C19, CYP2D6 in Chinese Han and Mongolian population. China Pharm. 2012;47:2017–2022.
   Google Scholar
• Mu D. Preliminary theoretical analysis of pharmacokinetics and metabolic differences between oxcarbazepine and carbamazepine. Tianjin: Tianjin University; 2006.
   Google Scholar
• Wang P, Lin XQ, Cai WK, et al. Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis. Eur J Clin Pharmacol. 2018;74(4):433–442.
   PubMed Web of Science ®Google Scholar
• Girard H, Villeneuve L, Court MH, et al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos. 2006;34(7):1220–1228.
   PubMed Web of Science ®Google Scholar
• Zhang W Analysis of the efficacy and influencing factors of oxcarbazepine in children with epilepsy. PhD Dissertation, Fujian Medical University: Fuzhou, 2019.
   Google Scholar
• Lu Y, Fang Y, Wu X, et al. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy. Eur J Clin Pharmacol. 2017;73(3):307–315.
   PubMed Web of Science ®Google Scholar
• Guo D, Pang LF, Han Y, et al. Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers. Eur J Clin Pharmacol. 2013;69(4):843–849.
   PubMed Web of Science ®Google Scholar
• Neumann E, Mehboob H, Ramírez J, et al. Age-Dependent Hepatic UDP-Glucuronosyltransferase Gene Expression and Activity in Children. Front Pharmacol. 2016;7:437.
   PubMed Web of Science ®Google Scholar
• He N, Zhao X, Zhang W. Research progress of relationship between the UGT2B7 genetic polymorphisms and the risk of cancers. Chin J Clin Pharmacol. 2015;31:1796–1798.
   Google Scholar
• Ma C Effect of gene polymorphism on the pharmacokinetics and pharmacodynamics of carbamazepine and its derivative oxcarbazepine. PhD Dissertation, Fudan University: Shanghai, 2013.
   Google Scholar
• Chung JY, Cho JY, Yu KS, et al. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008;83(4):595–600.
   PubMed Web of Science ®Google Scholar
• Shen C, Zhang B, Liu Z, et al. Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy. Seizure. 2017;51:102–106.
   PubMed Web of Science ®Google Scholar
• Chatzistefanidis D, Lazaros L, Giaka K, et al. UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels. Pharmacogenomics. 2016;17(8):827–835.
   PubMed Web of Science ®Google Scholar
• Bhasker CR, McKinnon W, Stone A, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics. 2000;10(8):679–685.
   PubMedGoogle Scholar
• Lazarowski A, Czornyj L, Lubienieki F, et al. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia. 2007;48(Suppl.):140–149.
   PubMedGoogle Scholar
• Kubota H, Ishihara H, Langmann T. Distribution and functional activity of P-glyeoprotein and multi-drug resistance-associated proteins in human brain microvascular endothelial cells in hippocarnpal sclerosis. Epilepsy Res. 2006;68(3):213–228.
   PubMed Web of Science ®Google Scholar
• Dallas S, Miller DS, Bendayan R. Multidrug resistanceassociated proteins: expression and function in the central nervous system. Pharmacol Rev. 2006;58(2):140–161.
   PubMed Web of Science ®Google Scholar
• Tazzite A, Kassogue Y, Diakité B, et al. Association between ABCB1 C3435T polymorphism and breast cancer risk: a Moroccan case-control study and meta-analysis. BMC Genet. 2016;17(1):126.
   PubMedGoogle Scholar
• Chouchi M, Kaabachi W, Klaa H, et al. Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis. BMC Neurol. 2017;17(1):32.
   PubMedGoogle Scholar
• Yue L The distribution of ABCB1 gene polymorphism in patients with epilepsy and its correlation with the efficacy of antiepileptic drugs. PhD Dissertation, Fudan University: Shanghai, 2010.
   Google Scholar
• Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005;76(1):22–76.
   PubMed Web of Science ®Google Scholar
• Lee G, Dallas S, Hong M, et al. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev. 2001;53(1):569–596.
   PubMedGoogle Scholar
• Chwab M S, Ezchelbaum M, Fromm MF. Genetic polymorphisms of the human drug transporter. Annu Rev Pharmacol Toxicol. 2003;43(1):285–307.
   PubMedGoogle Scholar
• Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev. 2002;54(10):1295–1310.
   PubMed Web of Science ®Google Scholar
• Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multi-drug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport. 2001;12(16):3557–3560.
   PubMed Web of Science ®Google Scholar
• Haufroid V. Genetic polymorphisms of ATP-binding cassette transporters ABCB 1 and ABCC2 and their impact on drug disposition. Curr Drug Targets. 2011;12(5):631–646.
   PubMed Web of Science ®Google Scholar
• Hung CC, Chang WL, Ho JL, et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics. 2012;13(2):159–169.
   PubMed Web of Science ®Google Scholar
• Ueda K, Taguchi Y, Morishima M. How does P-glycoprotein recognize its substrates? Semin Cancer Biol. 1997;45:424–429.
   Google Scholar
• Silvio B, Sanja H, Poljakovic Z. Comment letters. Epilepsia. 2006;47(2):449–452.
   PubMedGoogle Scholar
• Wang-Tilz Y, Tilz C, Wang B, et al. Influence of lamotrigine and topiramate on MDR1 expression in difficult-to-treat temporal lobe epilepsy. Epilepsia. 2006;47(2):233–239.
   PubMed Web of Science ®Google Scholar
• Volk HA, Loscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibitenhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain. 2005;128(6):1358–1368.
   PubMed Web of Science ®Google Scholar
• Rizzi M, Cacoia S, Guiso G. Limbic seizures induce P-glycoprotein in rodent brain:functional implications for pharmacoresistance. J Neurosei. 2002;22(14):5833–5839.
   PubMed Web of Science ®Google Scholar
• Lv Y, Yan Y, Wang X, et al. Antiepileptic drug-induced overexpression of P-glycoprotein-multidrug resistance gene in astrocytes in vitro. Chin J Neurol. 2001;34:42–44.
   Google Scholar
• Kwan P, Sills GJ, Butler E, et al. Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia. 2002;43(11):1318–1323.
   PubMed Web of Science ®Google Scholar
• Wu X, Shen D. Intractable epilepsy. Chin J Neurol. 1998;31:4–6.
   Google Scholar
• Ling V. Multidrug resistance: molecular mechanisms and mlinical relevance. Cancer Chemother Pharmacol. 1997;40(7):3–8.
   Google Scholar
• Hung C, Chen C, Lin C, et al. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008;18(5):390–402.
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97(7):3473–3478.
   PubMed Web of Science ®Google Scholar
• Zheng X Study on the relationship between the drug resistance of refractory epilepsy and the pharmacological mechanism of levetiracetam and the polymorphism of MDR1 C3435T. PhD Dissertation, Tianjin Medical University: Tianjin, 2009.
   Google Scholar
• Gao Q Study on population pharmacokinetics of levetiracetam and polymorphism of MDR1 C3435T in patients with epilepsy. PhD Dissertation, Fujian Medical University: Fuzhou, 2014.
   Google Scholar
• Tan N, Heron S, Scheffer I, et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology. 2004;63(6):1090–1092.
   PubMed Web of Science ®Google Scholar
• Kwan P, Baum L, Wong V, et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 2007;11(1):112–117.
   PubMed Web of Science ®Google Scholar